List of Small Molecule Pharmaceuticals Companies in New York - 121

A2A Pharmaceuticals designs computationally optimized small molecule therapeutics for the treatment of cancer and antibiotic resistant bacterial infections. Our two oncology programs are focused on inhibiting essential protein-protein interactions in leukemia and in diverse solid tumors. These interactions are critical for cancer progression, but non-essential in normal cells. The antibiotic programs target biosynthetic enzymes in gram-negative bacteria, in pathways not found in humans. The targets selected have no clinically used therapeutics, minimizing susceptibility to resistance; and unlike the numerous follow-on antibiotics currently in development. Our approach integrates interdisciplinary ingenuity with computational tools to design new drug candidates using our proprietary SCULPT platform. Experimentally determined target characteristics guide the selection and placement of fragments to recapitulate key contact points of proteins and/or ligands known to bind. Fragments are incorporated into the target-specific construction of combinatorial in silico libraries, which are designed based on synthetic feasibility. Libraries consisting of thousands to millions of small molecules are iteratively built, and computationally evaluated for potency and optimal ADMET properties. The final selection is made from dozens of iterations, totaling upwards of 100 million compounds.

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies.

Actylis is a chemicals company that specializes in acetates and provides pharmaceuticals, fine chemicals, and industrial chemicals.

Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.

Advion is a manufacturer and supplier of mass spectrometers and analytics systems for life science and pharmaceutical sectors.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore . Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Akelos Inc. is a biopharmaceutical clinical company focused on the translation of innovative science into treatment. The company currently is developing novel non-narcotic drugs for the treatment of neuropathic pain. The goal of Akelos is to address some of today’s most pressing areas of unmet needs. Over 21 million adults suffer from Neuropathic Pain in the US alone†, for which opioid medication is a common treatment. Associated costs exceed $90 billion/year in the US,† and roughly 40 ‐ 70% of people do not receive proper medical treatment and are at risk for either over‐ or under‐treatment.‡ Akelos: Building New Frontiers to Address Neuropathic Pain Akelos is an innovative research-based biotechnology company founded to address the Opioid epidemic through opioid alternatives, with two drug candidates in pre-clinical development. Akelos has proudly entered into a research collaboration to develop and commercialize a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain. Akelos holds an exclusive worldwide license with Columbia University and Cornell University and is working in collaboration with Weill Cornell Medicine. Researchers at Weill Cornell University and Columbia University have developed novel compounds for the treatment of neuropathic pain, resulting in intellectual property that is jointly owned by Cornell and Columbia. Akelos has licensed this intellectual property and is developing a treatment for neuropathic pain using the novel compounds.

Alpha-1 Biologics is a biotherapeutics company developing innovative treatments for cancers and immune deficiencies. The company is dedicated to their mission to develop patented therapeutics related to the generation of immune cells from stem cells within the body to treat immunodeficiency with disease applications including immune cell replenishment in cancer therapy, HIV/AIDS, patients with inherited deficiency of α1PI, and in the most prevalent cause of immune deficiency, malnutrition. Alpha-1 Biologics is currently testing their orally-available, small molecules in studies to determine their ability to increase the number of tumor infiltrating CD4+ T cells and coordinate with immune checkpoint inhibitors to eliminate tumors. The discoveries at the core of Alpha-1 Biologics therapeutic approach resulted from basic research conducted by Dr. Bristow and supported for many years by the non-profit research organization, Institute for Human Genetics and Biochemistry (IHGB) funded by the Harry Winston Research Foundation.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company focused on developing treatments for debilitating neurodegenerative and neurodevelopmental diseases. The Company’s lead product candidate, ANAVEX®2-73 is undergoing four mid- to late-stage clinical trial programs for CNS diseases where no good treatment options exist, or current treatments are inadequate. These include Alzheimer’s disease (Phase 2b/3) and Parkinson’s disease dementia (Phase 2), which are neurodegenerative diseases that are on the rise due to aging populations in developed nations. Additionally, Anavex has two ongoing Phase 2 trials for Rett syndrome, a neurodevelopmental disease that mostly affects young female girls. Anavex has received Orphan Drug Designation from both the FDA and EMA for Rett syndrome. ANAVEX®2-73 has potential to treat other CNS disorders, given its ability to restore upstream cellular homeostasis. Anavex has received funding from Rett Syndrome Foundation, as well as Michael J Fox Foundation supporting Anavex’s studies. Anavex has identified a novel biomarker signature (genetic variants) that have potential to determine which patients will benefit the most from ANAVEX®2-73, which targets the Sigma-1 receptor (SIGMAR1), a natural cell signaling pathway that is activated to restore cellular homeostasis.

AnHeart Therapeutics is a clinical-stage global biopharmaceutical group company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for the first-line TKI-naïve and second-line TKI-pre-treated patients with ROS1 fusion positive non-small cell lung cancer (NSCLC). The Company's pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors.

Applied Therapeutics is a clinical-stage biopharmaceutical company that uses our novel drug-development approach to create transformative, life-changing treatments for the patients who desperately need them.

Aquavit Pharmaceuticals, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, medical devices and health technologies. We focus on personalized medicine to improve patient health and to maximize the efficiency of the medical community. At Aquavit Pharmaceuticals, Inc., we combine this strategic focus with a modern, diverse approach that enables us to pursue new specialty areas with significant unmet needs. Science personalized. Healthcare modernized.

Argon AI is a platform that allows biopharmacy and life sciences experts to conduct complicated, data-driven operations. They help life sciences companies automate their data-intensive workflows with unprecedented AI.

ARMGO is a privately owned, venture-backed, biotech company that is developing small molecule drugs that repair leaky Ryanodine Receptor (RyR) calcium channels associated with human diseases. Our primary focus is on two orphan diseases: the life-threatening cardiac disease Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and the severe muscle disease RYR1-Related Myopathy (RYR1-RM). These two conditions occur due to genetic mutations in the RYR gene: RYR1 in RYR1-RM, and RYR2 in most CPVT cases. ARMGO’s molecules, termed Rycals® are designed to repair leaky RyR channels. Since the cause of the symptoms is abnormal calcium leak due to these mutations, Rycals hold the promise of disease-modifying therapy for these two orphan genetic diseases.

Developing Novel Therapies for Multiple Sclerosis

Auxilius Pharma is an emerging specialized pharmaceutical company with a focus on further developing and optimizing medications well established in some markets but not in the others, for the benefit of patients and to address major unmet needs in an increasingly cost conscious health care market environment. We are a versatile team with multifunctional healthcare experience in both the US and EU. We feature diverse backgrounds and strong core competencies in pharmaceutical marketing, drug development, pharmacology, health care management, corporate finance, and asset management.

Our Mission: For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines

Beyond Air Inc. is a commercial stage medical device and biopharmaceutical company focused on harnessing nitric oxide therapy. The company is built on a legacy of innovation and is revolutionizing nitric oxide therapy. Beyond Air Inc. has experience and leadership that go beyond, with a team of industry professionals dedicated to advancing medical treatment. For more information, visit https://www.beyondair.net/

BeyondSpring Pharmaceuticals is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes. The Company is developing treatments in two of the world’s largest markets, China and the United States. BeyondSpring’s first-in-class lead asset plinabulin, a selective immunomodulating microtubule-binding agent, is being developed as a “pipeline in a drug” with potential to be an anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). In the DUBLIN-3 Phase 3 study, the plinabulin and docetaxel combination met the primary endpoint of extending overall survival, compared to docetaxel alone in 2nd/3rd line non-small cell lung cancer (EGFR wild type). In addition, the plinabulin and G-CSF combination for the prevention of CIN has demonstrated positive Phase 3 data, for which it received Breakthrough status in the U.S. and China. Plinabulin is also currently being studied as part of other immuno-oncology (IO) combination regimens that include radiation and/or checkpoint inhibitors for the treatment of a number of cancers. Lastly, BeyondSpring also has three preclinical IO assets and majority ownership in its subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

BlinkRx is the world's first pharma-to-patient cloud that offers a digital concierge service for patients who are prescribed branded medications. Patients benefit from transparent low prices, free home delivery, and world-class support on this first-of-its-kind centralized platform. With BlinkRx, never again will a patient show up at the pharmacy only to discover that they can't afford their medication, their doctor needs to fill out a form for them, or the pharmacy doesn't have the medication in stock. We are a highly collaborative team of builders and operators who invent new ways of working in an industry that historically has resisted innovation. Join us!

BOC Sciences provides a wide variety of custom services which range from bulk compounds to specialty species in the pharmaceutical, agrochemical, and biotechnology industries. We are committed to providing our customers with the best products and services at the most competitive prices. Given diverse packing options for most of our chemicals, you are welcome to order the desired compounds in any quantities from a few mg to several kg along with all the relevant technical reports. We sincerely hope that our unremitting pursuits of excellence, success, and professionalism will add immense value to your research and development projects!

Bond Biosciences, Inc. is a privately held, clinical stage biopharmaceutical company focused on the discovery and development of first-in-class non-absorbed oral therapeutics that bind excess ions locally in the gastrointestinal (GI) tract to treat or prevent human disease.

BBI, headquartered in New York, is a privately held company founded in 2010 that specializes in acquiring and developing pharmaceutical and biotechnology products intended for the treatment and/or prevention of serious unmet medical needs. The COMPANY’s focus is to develop its products as quickly and as efficiently as possible, saving time and resources. We have partnered with leading academic institutions as well as a global network of drug development resources, eliminating the need and cost to build a "brick and mortar" biotech company. This innovative approach gives BBI big pharma capabilities without a big pharma infrastructure.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company’s products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Cambrian Bio is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health.

Canget BioTekpharma is a biotech and biopharma company used to develop novel, cancer-targeting anticancer agents.

CD BioGlyco provides various carbohydrates, glycoconjugates, enzymes and related products, as well as many glycobiology related research services.

CD Bioparticles is an established drug delivery company which provides customized solutions for developing and producing new, biocompatible drug delivery systems.

Celmatix Inc. is a preclinical-stage women’s health biotech focused uniquely on ovarian biology. With a lead “pipeline-in-a-pill” AMHR2 program focused on ovarian senescence, and collaborations in PCOS and non-hormonal contraception with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health. Celmatix’s proprietary multi-omic ovarian health platform, the world’s largest of its kind, is the foundation of the company’s novel pipeline of first-in-class therapies. For more information visit www.celmatix.com.

CMTx Biotech is commercializing a pipeline of proprietary, non-antibiotic, chemically-modified tetracycline (CMT) compositions and formulations for the host-modulatory treatment of diseases with high unmet needs. The company’s lead drug candidate is a clinical-stage, orally-administered small molecule (incyclinide / CMT-3 / COL-3) for the treatment of hospitalized sepsis patients at risk of septic shock, multiple organ dysfunction syndrome (MODS) and acute respiratory distress syndrome (ARDS), including from SARS-CoV-2 infection (COVID-19) and other infectious diseases. Our clinical-stage drug candidate has already demonstrated impressive efficacy in a number of animal models of sepsis/ARDS/MODS across multiple species (rats, mice, pigs, sheep). It has also been evaluated in over 450 patients across eleven Phase I/II clinical studies, which showed that the drug is well-tolerated. CMTx Biotech also has a pipeline of pre-clinical stage analogues for the treatment of diseases with high unmet need.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer’s disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer’s disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson’s disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

ConSynance is a clinical-stage virtual biopharmaceutical company focusing on rare diseases in the central nervous system. Our lead asset is CSTI-500, a small molecule first-in-class triple monoamine reuptake inhibitor (TRI) with the potential to benefit patients with Prader-Willi syndrome (PWS) and other related disorders. CSTI-500 was generally safe and well-tolerated in Phase I clinical trials in healthy humans and demonstrated CNS target engagement via PET that predicts efficacy in patients. ConSynance is currently recruiting for a Phase I study in PWS patients (clinicaltrials.gov: NCT05504395) to study the pharmacokinetics and safety in this patient population. We also have a preclinical candidate, CSTI-200, a small molecule, first-in-class GlyT-1 Inhibitor for the treatment of L-Dopa-induced dyskinesia (LID) in Parkinson’s disease (PD). Based on recent preclinical evidence, GlyT1 inhibition may have a niche in PD not only for the treatment of dyskinesia, but motor fluctuations and PD psychosis. CSTI-200 has a competitive mechanism of binding that provides a “self-regulating” property for potentially better tolerability compared with non-competitive GlyT-1 inhibitors. In 2021, we reached an asset purchase agreement with Harmony Biosciences for our second drug, (formerly CSTI-100, now renamed HBS-102.) This potential first-in-class MCHR1 antagonist has the potential to treat a variety of neurological disorders. ConSynance currently holds the license of this drug for the Greater China region and Harmony has global commercialization rights outside of Greater China.

Creative Bioarray uniquely pioneers the development of high quality tissue, antibody, protein and cell array technology to efficiently analyze the concurrent expression and function of proteins involved in inflammation, angiogenesis, apoptosis, cell growth, and signal transduction from a single biological sample. Creative Bioarray is a well-recognized service provider propelled by integrity, expertise and the desire to contribute to simplify, improve, and accelerate research speed of the scientists by providing the highest standard quality research products and services. Since it founded, Creative Bioarray had recognized that an important obstacle to make development of basic bioscience and preclinical researches using human specimens is the lack of access to reference materials. Consequently, Creative Bioarray was determined to be the first commercial entity specialized in building up the largest tissue-sharing platform by integrating the detailed clinical information of all the tissue samples.

Creative Biostructure is specialized in providing cost-effective contract services to both academia and biotech/pharmaceutical industries in the field of structural biology and membrane protein technologies. We have developed all-in-one, gene-to-structure pipelines for the structure determination of macromolecules of your interest. With a team of experienced professionals, Creative Biostructure is able to solve the structure of many challenging proteins including GPCRs, ion channels, transporters, enzymes and viral targets. We also provide a comprehensive list of products and other related services to facilitate your research in structural biology. Creative Biostructure has also built up a unique and comprehensive Membrane Protein Screening Platform. Aiming at elucidating the fundamentals of membrane protein systems, we provide gene-to-structure services on the purification, crystallization, structure determination and analysis of various membrane proteins. With our state-of-the-art platforms, we are offering our customers access to the latest tools, techniques and expertise for their structural biology projects with competitive pricing and short turnaround time. Our staff will be very glad to discuss the details of your project and develop experimental strategies tailored to your requirements.

Creative Peptides is specialized in the process development and the manufacturing of bioactive peptides. They offer custom peptide synthesis, process development, manufacturing as well as catalog products for customers in industry and research area.

Curemark is a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for neurological and developmental disorders. Our diverse pipeline spans multiple critical areas of unmet need, including Autism Spectrum Disorder (ASD), Amyotrophic Lateral Sclerosis (ALS), Addiction, Attention-Deficit/Hyperactivity Disorder (ADHD), Schizophrenia, and Parkinson’s Disease. At the heart of our mission is a commitment to addressing the root causes of these conditions, not just managing symptoms. Our lead investigational therapy targets key enzyme deficiencies associated with autism, offering a novel approach to treatment for a condition that affects millions worldwide. Our pipeline reflects a science-driven, patient-first approach with a focus on discovering and developing transformative therapies for complex neurological conditions. By exploring the role of enzymes and their impact on brain function, Curemark aims to deliver targeted, effective treatments that improve patient outcomes. With a commitment to scientific excellence, strategic collaboration, and a deep focus on patient well-being, Curemark is reshaping the future of neurological care. Our goal is to offer life-changing solutions for individuals living with autism, ALS, addiction, ADHD, schizophrenia, Parkinson’s disease, and other challenging conditions. Stay connected with us as we continue to push the boundaries of discovery and bring new hope to patients, families, and caregivers. For more information, visit Curemark.com.

Curia is a Contract Development and Manufacturing Organization with over 30 years of experience, an integrated network of 25 global sites and 3,500 employees partnering with customers to make treatments broadly accessible to patients. Our biologics and small molecule offering spans discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate and sustain life-changing therapeutics. To learn more visit us at curiaglobal.com ************************************************** ⚠️NOTICE: Please Be Aware of False Employment Opportunities ************************************************** Please be aware there has been reported fraudulent activity within our industry regarding false offers being made to applicants and requests for personal information from individuals or organizations posing as company representatives. Any applicant who applies to Curia must submit their application through Curia’s career page at https://careers.curiaglobal.com. Applicants will only receive communication, including offer letters, from a curiaglobal.com email address. Please be aware that recent scams used email addresses that are similar to Curia addresses or use other public domain addresses such as gmail.com, yahoo.com and aol.com. Please confirm the sender’s email address prior to sharing your information.

Curie Co fashions biological solutions from the basic building blocks of life. Curie Co’s enzyme optimization platform teaches abundant, naturally-occurring enzymes to perform the same function as legacy preservatives and with efficiency that is orders of magnitude better. Our enzymes are gentle for people and the planet–they are fully biodegradable and sustainably derived. From hand soap, body wash, hair care products, skincare, and beyond, we give product formulators the freedom to build a powerful, long-lasting product that is nature-based from the bottom up. Founded in 2017, Curie Co is a collection of top scientists from Fortune 500 companies around the globe. Our interdisciplinary team unites under the belief that sustainability is not a luxury, it’s our obligation. Curie Co is proudly based in Research Triangle Park. To learn more, please visit: https://www.curieco.com/.

Cypris Therapeutics is a chemistry-focused pharmaceutical start-up that uses proprietary synthetic chemistry and drug development skills to produce effective therapeutics. The company has launched as the newest Ichor Life Sciences portfolio company and has secured over $500k in pre-seed funding. As the company moves forward, it continues to seek additional funding and partnerships to support its ambitious goals.

Delcath Systems, Inc. (NASDAQ- DCTH) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. Our proprietary product---Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. Delcath is in late-stage clinical development in the United States with initial commercial activities in Europe, where the Melphalan/HDS is marketed as a CE Marked device under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). Our commercial strategy for CHEMOSAT is to steadily grow clinical adoption in major European markets and utilize physician experience to support appeals for reimbursement. Since launch over 250 CHEMOSAT treatments have been performed at over 20 leading European cancer centers. In 2016, we launched our FOCUS Pivotal Study in Hepatic Dominant Ocular Melanoma, and are investigating orphan indications in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. We believe Melphalan/HDS is uniquely positioned to treat the entire liver as a stand-alone or complementary therapy.

DepYmed is currently developing potent inhibitors of the enzyme PTP1B as therapeutics for cancer and rare diseases. In addition, DepYmed has developed a portfolio of novel small molecules with copper chelating properties that can be applied as potential therapeutic agents for multiple diseases including Wilson Disease and cancer. ​

Private biotech company leveraging immuno-metabolism to create a potential new treatment paradigm with broad application for many cancer types.

Empyrean is harnessing the power of genetic engineering to transform how we treat severe neuropsychiatric and neurologic diseases.

ENB Therapeutics is developing therapies to break drug resistance that occurs in over 50% of cancer patients. Our lead product, ENB-001, is a first-in-class, selective small molecule endothelin B receptor (ETBR) inhibitor shown in multiple preclinical studies to significantly reduce tumor growth and prolong survival in cancer animal models. ENB-001 is the key to unlock the full therapeutic potential of immunotherapy by restoring the ability of T-cells to infiltrate tumors, inhibiting metastasis and prolonging patient survival. Granted Orphan Drug Designation by FDA in 2016, ENB-001 has solid market exclusivity and strong IP. A low cost, time efficient development program provides near-term POC within 18 months from financing. A companion diagnostic will detect ETBR pathway over-expressers creating additional opportunities for indication expansion into multiple tumor types and broader participation in the multi-billion-dollar immunotherapy market.

Eyenovia, Inc. (NASDAQ: EYEN) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.

Formation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.

FREZENT is a preclinical stage oncology therapeutics company based in New York. The company is developing bispecific antibodies and antibody-drug conjugates for targeting dormant cancer cells that may cause cancer recurrence. Dormant cancer cells are tiny residual parts of a tumor, that was not completely eliminated by the treatment. They can remain in the body undetectable for a period of time but eventually these cells can transform back into a fast growing tumor. FREZENT is developing a novel cancer treatment that will block the reactivation of dormant cancer cells. To achieve this goal, we are developing novel cancer therapeutic that can neutralize metabolic factors supplied tumor microenvironment to support the dormant cancer cells. Being in a dormant state, cancer cells depend on these external supplies, and thus blocking this supply will starve cancer cells and induce cell death. Join us in our mission to ensure the future where long-lasting remission is the reality for ALL cancer patients.

Gilgamesh is a clinical-stage biotech whose vision is to reshape how mental illnesses are treated by shifting away from symptom management to a focus on rapid-acting and durable therapies targeting the fundamental drivers of disease. We do this by designing best-in-class new chemical entities (NCEs) acting through proven mechanisms, which are optimized for safety, efficacy, and patient access

Neurodevelopmental disorders represent significant areas of unmet need in healthcare. People affected by these disorders, predominantly children and young adults, can face a range of severe and devastating symptoms. In many cases, there are only limited or no treatments available. GRIN Therapeutics is dedicated to the research and development of precision therapeutics for pediatric neurodevelopmental disorders with the goal of bringing hope to patients and caregivers.

Hemogenyx Pharmaceuticals PLC is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located at its state-of-the-art research facility in New York City. For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx Pharmaceuticals plc’s technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation. Hemogenyx Pharmaceuticals PLC is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. The Company is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both completing Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently in Phase 2 clinical development, modulates the anti-tumor innate immune response.

At Hoth Therapeutics, Inc. (NASDAQ: HOTH), we strive to develop innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating promising drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate medications that hold immense potential to create breakthroughs and diversify treatment options.

Ichnos Sciences is a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology and disease-centric therapies.

ICPD began by integrating pre-clinical and clinical data through modeling and simulation to improve how antibiotic resistance is defined in the clinical microbiology laboratory. ICPD then ignited the use of PK-PD-based dose regimen selection that now ensures optimal patient drug exposures and thus, an increased likelihood of successful response during the antibiotic development process. ICPD educates drug regulators and pharmaceutical and biotechnology companies on PK-PD-based strategies to make certain safe and effective antibiotics are available to thwart the growing threat of antibiotic-resistance. ICPD Technologies has used the foundation laid by ICPD and others to develop a mobile device application that provides PK-PD education to clinicians. Through the revolutionary PK-PD Compass, ICPD Technologies will carry out a mission to educate clinicians and improve antibiotic stewardship efforts worldwide.

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis.

IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio develops ex vivo-expanded and activated gamma-delta T cells based upon its deep expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific manufacturing capabilities, which we refer to collectively as our DeltEx platform. IN8bio’s platform employs allogeneic, autologous, and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. IN8bio is currently the most clinically advanced gamma-delta T cell company and the first company to bring genetically modified gamma-delta T cells into the clinic. For more information about the Company and its programs, visit www.IN8bio.com.

INNOVIMMUNE is a specialty Drug Discovery & Exploratory Development biotechnology company leading the development of novel first-in-class and best-in-class proprietary oral small molecule NME immunomodulatory drugs for the treatment of Autoimmune, Inflammatory and Oncologic Diseases. Follow us on Twitter: @Innovimmune

Inspirna is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Inspirna's founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways. Our discovery platform - which can be applied to virtually any tumor type - has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies. Our lead therapy RGX-104 is a small molecule immunotherapy that blocks the ability of tumors to evade the immune system. RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need and entered clinical trials in Q4 2016.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company founded on Nobel prize-winning research that allows it to understand how therapies affect the inner-workings of cells in the body. The Company leverages this intracellular approach to deliver innovative treatments for people living with complex psychiatric and neurologic diseases. WORK WITH US Patient needs are at the core of our efforts at Intra-Cellular Therapies and we are always looking for talented individuals who share our values to join our team. Please explore open positions by clicking the “Jobs” tab above.

iuvo BioScience is a contract research organization serving the pharmaceutical and medical device industries. Our services encompass pre-clinical research, clinical research and consulting services. With a focus on safety and biocompatibility, iuvo provides assistance through the full product development life cycle, from research to release, including ISO 10993:2018 testing as well as testing programs and advisory services to support regulatory submissions. We have an AAALAC-accredited vivarium and offer full service, GLP-compliant toxicology testing, as well as microbiology and analytical chemistry testing laboratories. We are certified to ISO 13485:2016 and accredited to ISO 17025:2017 quality system standards. We bring decades of experience supporting healthcare and medtech companies of all sizes from around the world, and we work closely with our customers to deliver exquisite science, reliably and on time. Come to us with a specific test, a full program you need managed, or even a research question you need help answering. We are your Partner Research Organization.

At Kallyope, we focus on big health challenges that matter to patients and families. We aim to discover and develop effective, easy to use, and well-tolerated oral agents addressing metabolic, neurological, and gastrointestinal diseases. Inside every human body is a complex, unexplored network of metabolic, neurological, and gastrointestinal interconnections. Our scientists are unlocking the mysteries of this network to develop oral therapies for obesity and diabetes; neurological disorders, including migraine; and gastrointestinal disease, including celiac disease. Based in New York City, we are home to some of the world’s most intrepid scientific minds from the world’s top institutions, working alongside a seasoned team with a proven track record of success in drug discovery and development. Together, we are leveraging multiple sophisticated technologies and internally-developed capabilities to bring fundamentally new solutions to some of the most pressing unmet needs in human health.

LB Pharmaceuticals is a development stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed in the United States. We believe that there are a number of ‘gold standard’ CNS therapies with excellent safety and efficacy profiles that, for various financial reasons, have never become FDA approved. Our approach is to create a research-focused organization dedicated to generating novel intellectual property around improved versions of these former best-selling drugs. We have a low-risk, high-reward drug development business plan: invest in bringing to the US market patented, branded, first-to-market versions of standard-of-care CNS therapies currently in use worldwide.

Leal Therapeutics is a biopharmaceutical company that focuses on developing novel therapeutics for patients with major disorders of the central nervous system.

Lento Bio was formed in 2022 in partnership with Ichor Life Sciences, with the goal to develop effective, safe, and durable treatments for chronic age-related disease by using small molecules to directly target molecular damage.

Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. The phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. The lead compound LB-100 is in Phase I trial and has the potential to be first-in-class. The deacetylase inhibitors have anti-cancer activity and in model systems correct enzymes deficiencies underlying several inborn metabolic diseases including Gaucher and von Hippel-Lindau disease and neurofibromatosis type 2. Lixte's cancer drug development strategy has led to the discovery of novel compounds with the potential to be therapeutically useful against several other important but seemingly disparate diseases. The phosphatase inhibitors are in pre-clinical development for reducing the extent of tissue damage following stroke, heart attack, and septic shock; and, the deacetylase inhibitors for prevention and treatment of neurodegenerative diseases, traumatic brain injury, and topically for fungal dermatitis .

American Regent, Inc, a Daiichi Sankyo Group Company, develops, manufactures, and supplies high quality sterile injectables for healthcare providers, clinics and hospitals across the United States and Canada. We have locations in New York, Ohio, and Pennsylvania and sales territories nationwide. American Regent continues to position its business for sustainable growth, with significant investments in the modernization and expansion of our U.S. manufacturing sites. These enhancements are expected to strengthen our business and represents our commitment to the ongoing success of our company and its employees. Supporting patient health is our guiding principle and our promise is to provide the healthcare marketplace with a steady supply and broad portfolio of brand and generic specialty injectables.

MABLYTICS is a biotechnology company that specializes in developing immunotherapies using a novel target with applications in cancer research.

At Martin Pharmaceuticals we are passionate about bringing life-changing advances to patients with rare diseases or challenging medical conditions. We aspire every day to make a real difference in people's lives, turning hope into answers.

Matexcel is a service provider in materials science, with years of commitment to supply better polymers, nanoparticles and other materials for worldwide customers from both academia and industry. They offer a full range of materials covering polymers, metals, ceramics and natural materials, in addition to professional consultation service in manufacturing and characterization. Our experienced team of scientists have mastered a wide spectrum of technologies to solve interdisciplinary tasks such as custom synthesizing and developing polymeric and nano-bio applications. They are a customer-oriented company aiming to deliver product and service to the global pharmaceutical and nano-biotechnology markets.

Millennial Scientific manufactures sustainable separation and purification materials for the discovery, R&D, and manufacturing of pharmaceuticals and other chemicals. Our product portfolio includes the award-winning NanoPak-C all-carbon suite of chromatography products. These products enable economical (e.g., operation cost reduction) and better (e.g., yield improvement) performance. These products are available as bulk stationary phase media or packed in solid-phase extraction (SPE) and liquid chromatography columns. We are ISO 9001:2015, MBE (New York State (NYS)), and DBE (Metropolitan Transportation Authority (MTA)) certified.

MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low intensity acoustic technology. The company's patented technology allows for creation of miniature transducers that transmit low-frequency, low-intensity ultrasound through flexible material surfaces. This unique development may be utilized for a variety of medical requiring low cost therapeutic ultrasound applications. The company's patch based product diagnosis, PainShield®, carries an FDA clearance. NanoVibronix catheter based products include the CathbotTM . NanoVibronix Inc. is located in Elmsford, NY. Its subsidiary, NanoVibronix Ltd. is located in Nesher, Israel.

New Amsterdam Sciences is a development-stage bioscience company focused on the research, development and licensing of analogues of Substance P. NAS911B is the company's lead compound, and is being pursued for indications including idiopathic pulmonary fibrosis, influenza infection, wound healing and solid tumors. New Amsterdam Sciences is devoted to developing products for both the commercial market and government markets, with exceptional candidates for mass-casualty biodefense applications specifically addressing acute radiation sickness (neutropenia), chemical exposure and biological warfare scenarios. To complete this mission, the company has cultivated numerous study partnerships with industry and academic leaders, including the Vaccine and Gene Therapy Institute of Florida, the University of Rochester, Harvard School of Medicine, and more. For additional information, please visit www.newamsterdamsciences.com

NomoCan Pharmaceuticals offers first-in-kind targeted therapies for some of the most aggressive cancers with unmet medical need. Our platform technology not only makes available a selective and specific diagnostic and prognostic test for early detection, but more remarkably, it introduces a highly effective therapeutics for the treatment of various cancers in order to “Bring Hope” to patients affected by this devastating disease.​

Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma and breast cancers, among others. By selectively targeting NLRP3, the body’s first line response in the innate immune system, Olatec’s lead compound, dapansutrile (lab code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL 1B and IL 18. Olatec’s drug development team, working together over 10 years, is comprised of experienced management and international thought leaders that have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today. The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands.

Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma and breast cancers, among others. By selectively targeting NLRP3, the body’s first line response in the innate immune system, Olatec’s lead compound, dapansutrile (lab code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL 1B and IL 18. Olatec’s drug development team, working together over 10 years, is comprised of experienced management and international thought leaders that have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today. The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands.

Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. With a focus on oral, small molecule, tau self-association inhibitors, Oligomerix seeks to develop therapies for Alzheimer’s disease and other dementias that are easy to administer and cost effective, and which are expected to significantly add to newly emerging high-cost therapeutic options such as the monoclonal antibody targeted against beta-amyloid that was recently approved by the U.S. FDA. Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.

OnCusp Therapeutics is transforming a growing portfolio of cutting-edge molecules into innovative treatments that deliver help and hope to cancer patients worldwide. The company is led by a founding team that has deep experience in business development, clinical development and building start-up biopharmaceutical company. OnCusp continually strives to optimize the largest value inflection point in the drug development value chain and believes that accelerating oncology drug innovation is the best way to deliver help and hope to cancer patients worldwide. OnCusp completed a $25m seed round from investors including Sequoia Capital China, Biotrack Capital, Oriza Seed Fund, and AIHC Capital. OnCusp has offices in New York and Shanghai.

A small, privately-held, and family-focused neonatology pharmaceutical company, ONY Biotech is a leader in the creation of critically important products for the treatment of premature infants. We innovate with a singular purpose: to improve outcomes for premature babies and their families. As a USA-born neonatology biotech, we take pride in the work we do delivering treatments that serve families here in the United States and around the world.

Oramed Pharmaceuticals (NASDAQ:ORMP) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. Through its patented flagship product, an orally ingestible insulin capsule currently in Phase 3 trials under the USFDA, the Company is seeking to revolutionize the treatment of diabetes. Read more: http://www.oramed.com/investors/corporate-presentation Watch: https://www.youtube.com/watch?v=5qChxTDV9eg Terms and conditions and privacy policy: https://www.oramed.com/web-site-terms-and-conditions/

Oravax Medical is developing an oral COVID-19 vaccine. The Oravax technology seamlessly integrates a novel approach to vaccines with a proprietary oral delivery platform. Oravax's COVID-19 vaccine candidate benefits from being a virus like particle (VLP) triple antigen vaccine that targets three structural proteins, which should make it a better candidate for protection across emerging mutations of the coronavirus. The oral delivery of the vaccine ought to allow for widescale inoculation and easier distribution of the vaccine without requiring an injection. Oravax was established by Oramed Pharmaceuticals Inc., the largest shareholder in Oravax, along with Premas Biotech with a mission of bringing an oral COVID-19 vaccine to the market.

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. Ovid’s most advanced investigational medicine, OV101 (gaboxadol), is currently in phase 3 clinical development for the treatment of Angelman syndrome with data expected in the 4Q 2020 and in earlier clinical development for Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare developmental and epileptic encephalopathies (DEEs) and expects to initiate pivotal trials for OV935 in 2021.

Oviva is a premier biotech company developing first-in-class therapeutics to improve ovarian function and consequently extend female healthspan. Oviva is leading a movement to improve women’s experience of aging through biomedical research, clinical development and advocacy. While driving tangible progress through therapeutics programs, Oviva is engaging with scientists, clinicians, policy makers and the general public to elevate, and equalize, the conversation around women’s health. In bringing together stakeholders across disciplines, we are inviting diverse perspectives and skill sets to drive innovation and progress in this space.

Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner. We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).

Perception Neuroscience is developing PCN-101 (Arketamine, or R-ketamine) with a vision of providing significantly improved solutions to serious mental health disorders.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

PLD is a leading supplier of over-the-counter solid and liquid dose remedies in the Analgesic, Cough/Cold, Allergy, Sleep/Awake/Motion, Digestive, Nutritional, First Aid, Electrolyte and Epsom Salt categories. We pride ourselves on delivering the highest quality product in the most cost-efficient manner possible. This includes adhering to cGMP and stringent FDA regulations, so every product we manufacture meets and even exceeds the industry's rigorous standards. Since we began in 1988, it is our unwavering commitment to excellence that has enabled us to grow to serve every major retailer in the U.S. and many around the globe. Today we remain at the forefront of the consumer healthcare industry with 1,000+ dedicated employees and more than 1,000,000 sq. ft. of state-of-the-art facilities across New York, California, Florida and South Carolina. Our Mission To provide high quality and affordable healthcare products that help people feel well through services that cultivate trust and confidence. We foster an environment where people are passionate about their work and the wellbeing of their communities. Our Vision To be the most respected, efficient, and reliable partner delivering healthcare products and services that improve People's Lives Daily. Interested in a career at PLD? Please visit: http://www.pldevelopments.com/careers/

ProJenX is a clinical-stage biotechnology company with novel, targeted, brain-penetrant therapies to address neurodegenerative diseases, with an initial focus on ALS. ProJenX was created out of a long-term research collaboration between Project ALS and Columbia University to rapidly develop and commercialize its lead therapy candidate, prosetin, for people with ALS. At the heart of ProJenX’s discoveries is an innovative, patient-specific, cell-based discovery platform that can be leveraged for the creation of additional transformative neuroscience medicines.

Promontory Therapeutics is a private, clinical stage biopharmaceutical company founded in 2010, and funded by private investors and family investment offices in the U.S., Europe and Asia. It holds the exclusive, global license to phosphaplatins, a family of novel agents currently in clinical development for the treatment of both solid tumors and hematological cancers. Phosphaplatins are the result of over 20 years of work by the inventor, and uniquely combine an immunological form of apoptosis with an attractive safety profile. The lead agent is the subject of two approved IND applications with the US FDA, and of a collaboration and option agreement for rights in Greater China with SciClone Pharmaceuticals.

Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.

Q BioMed Inc. is a biotech acceleration and commercial stage company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Remedy Pharmaceuticals, Inc., located in New York City, is a late-stage specialty pharma focused on therapies capable of transforming treatment in the management of life-threatening brain edema-related conditions − where there are inadequate or no approved existing therapies. CNS-related edema (swelling) is a large unmet medical need that carries significant mortality, morbidity and societal burdens. Solve the problem of edema and you have taken the biggest step forward in the history of treating these patients. How large is this opportunity? For instance, there are 110,000 LHIs in the U.S. each year. CNS-related edema is present in multiple critical care indications, i.e., LHI, subarachnoid hemorrhage, intracerebral hemorrhage, traumatic brain injury, cardiac arrest, spinal cord injury, etc., as well as in chronic conditions such as brain tumors (primary and metastases). For more information, go to:http://www.remedypharmaceuticals.com

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

Founded in 2008, S1 Biopharma is developing first-in-class drugs for the treatment of sexual dysfunction and hypoactive sexual desire disorder (HSDD) in both women and men. The company’s non-hormonal therapies work uniquely by restoring the natural balance of neurotransmitters in the brain. Since our company’s inception, we have been committed to innovation, integrity, the use of the highest quality science and a deep understanding of the biology underlying these disorders to develop effective treatments with safety as a priority. See our social media community guidelines at http://bit.ly/1kLpD6M

Schrödinger, Inc. provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. Its segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment develops a pipeline of preclinical and clinical drug discovery programs through its computational platform in collaboration with pharmaceutical companies. Schrödinger, Inc. has strategic collaborations with Twist Bioscience Corporation; Thermo Fisher Scientific to extend the use of cryo-EM in connection within silico compound screening to accelerate drug discovery; and Bristol Myers Squibb Company to discover, develop, and commercialize therapeutics in multiple disease areas. The company was founded in 1990 and is based in New York.

ScieGen Pharmaceuticals Inc. is a fast growing generic pharmaceutical manufacturer located in Hauppauge, NY.

Seed Therapeutics is pioneering the science of improving human health by creating “molecular glues”: novel therapeutics that degrade disease-causing proteins that have heretofore remained “undruggable.” Through ongoing collaborations with world-leading academic experts in the field, and in partnership with seasoned drug development and commercialization experts, Seed Therapeutics is establishing a growing pipeline of exciting drug candidates on a path to clinical and commercial success. Our mission is to positively impact human health by creating novel protein degradation therapeutics for the treatment of severe diseases for which health care professionals currently have limited options to offer to patients.

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b clinical trials for the treatment of early stage breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.

Sen-Jam Pharmaceutical is focused on improving clinical outcomes for patients battling inflammation-based diseases such as viral respiratory infections from coronaviruses such as COVID-19 and other painful inflammation and toxin-induced conditions, including arthritis, vaccinations, opioid withdrawal and even the infamous hangover. Using our patented proprietary technology of “next generation anti-inflammatories” and the accelerated 505(b)2 pathway, we’re addressing the root causes of autoimmune inflammation—much like how Ozempic targets metabolic inflammation.. Our mission: to transform how we treat inflammation and reshape the business of pain relief for the betterment of humanity..

SIGA is a leader in global health, developing medicines to prevent and treat emerging infectious diseases with high unmet medical needs. Infectious diseases pose an imminent and severe threat to global health that cannot be adequately addressed with vaccines alone. Smallpox, mpox, and other orthopoxviruses are particularly worrisome because they are highly infectious and deadly. We are developing best-in-class products to treat these infections in patients worldwide.

Sparian Biosciences is an early-stage CNS-focused biopharmaceutical company committed to developing novel, transformational therapies. Diseases of the central nervous system represent a major unmet need but recently there has been little innovation and development. Sparian was co-founded by Gavril Pasternak, MD PhD and Jeff Reich, MD to develop therapeutics targeting the brain through innovative science and novel drug discovery. Currently, we have 4 programs addressing various aspects of the opioid crisis - a crisis in urgent need of innovation. Two of our compounds come from the Pasternak Lab at Memorial Sloan Kettering Cancer Center, one comes from the USC Michelson Center for Convergent Bioscience and one comes from a collaboration with Washington University. Core to our strategy, we have ongoing scientific and clinical collaborations with MSKCC, Washington University, St. Louis College of Pharmacy, Rutgers University Medical School, University of Florida, and the U.S. Department of Defense. Sparian is based out of BioLabs@NYULangone in NYC, a national biotech incubator, and is a member of the StartupNY program.

Stablix is pioneering an entirely new field of targeted deubiquitination therapeutics (TDT) to bring transformative medicines to patients with unmet medical need. Co-located in New York City and Boston, we are a creative and multidisciplinary team of scientists, innovators and leaders dedicated to changing the way we approach drug development by establishing a powerful small-molecule modality for a wide variety of devastating diseases.

Stelexis is a Deerfield founded and solely funded New York-based cancer therapeutics company with a mission of transforming cancer therapeutics paradigm and patient care, through the discovery and development of novel drugs. Stelexis proprietary platform is focused on identifying, isolating and studying the earliest definable stem and progenitor cells, which harbor clonal properties and pre-cancerous alterations, that drive the formation of primary and recurrent human tumors. Stelexis utilizes this powerful platform as a target identification engine and drug discovery and development tool to address unmet needs in multiple cancer indications. Deerfield founded Stelexis Therapeutics in 2017 together with scientific founders, Drs. Ulrich Steidl, Evripidis Gavathiotis, Amit Verma and Roman Perez-Soler of Albert Einstein College of Medicine, Montefiore Medicine, New York and Dr. Derrick Rossi of Boston Children’s Hospital, Harvard Medical School.

Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline commercializes Elzonris®, a novel targeted treatment directed to CD123 for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematologic cancer, in the United States and Europe, the only approved treatment for BPDCN in the US and EU to date. Stemline also commercializes Nexpovio® in Europe, an XPO1 inhibitor for multiple myeloma originating from a licensing deal with Karyopharm. Stemline has an extensive clinical pipeline of small molecules and biologics in various stages of development for a host of solid and hematologic cancers.

Summit Biomedical Imaging, LLC., a spin-off company from Memorial Sloan Kettering Cancer Center (MSK, New York City), was founded by Thomas Reiner and Christian Brand in 2016. Recently, Summit Biomedical Imaging was awarded a federal grant through NIH's Small Business Innovation Research (SBIR) program, also known as America's Seed Fund, to support the strong potential of commercialization of their innovative biomedical technology. This early-stage funding from the National Cancer Institute (NCI) allowed them to open their Research and Development facilities in the heart of New York City to develop novel targeted cancer diagnostics.

Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease

Traverse Biotech develops innovative internationally sourced technologies from the pre-clinical stage through clinical proof-of-concept, driving significant value for shareholders and maximizing patient benefit.

Treadwell Therapeutics is a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers by targeting critical tumor-specific vulnerabilities including aneuploidy and immunogenicity. The Company’s robust, internally developed pipeline includes novel small molecule drugs in single agent and combination studies. Lead candidate, CFI-400945, is a PLK4 inhibitor in multiple Phase 1 and Phase 2 trials including for TNBC, prostate cancer and AML. Additional product candidates include CFI-402257, a clinical stage TTK inhibitor, as well as CFI-402411, a preclinical HPK1 inhibitor (IND filing 1H20), which is positioned to be the first clinical stage small molecule modulator of a unique node of T cell activation and has a mechanism distinct from PD1/PDL1.

We are UTR Therapeutics Inc. a pre-clinical NYC based biotech born from the Nucleate Activator Program. Our technology is a breakthrough discovery which can overwrite any endogenous transcript. The technology can uniquely target and degrade any transcript of interest which we have proven in multiple difficult to treat cancers. Learn more by visiting us at www.utrtherapeutics.com or contacting us at chidi@utrtherapeutics.com Notable Recognitions 2022: Nucleate Genentech Award Illumina Accelerator Sequencing Grant 2023: Deerfield Management and Economic Development Committee of NY xSeed Award 40 under 40 in Cancer [Chidiebere Awah], Association of Value Based Cancer Care (AVBCC) July 31 2023- Pre-IND Feedback from FDA for UTRxM1-18

Verra Therapeutics is a privately held company near Ithaca NY, that was founded in 2017 with a mission of transforming the treatment of protease-driven diseases using an innovative small protein platform. Verra is developing preclinical drug candidates for Chronic Bronchitis, Acute Lung Injury and Acute Kidney Injury by adapting nature’s highly evolved design for each target protease. Dr. Christopher Prince brings decades of leadership experience to the team in managing technology companies through biotech and pharmaceutical development. Dr. Marcia Moss has a comprehensive background in drug discovery and development and is a thought leader on proteases as disease targets. Verra’s goal is to create novel, selective and impactful drugs for patients with major unsolved medical illnesses.

Visiox biopharmaceutical company focused on the development and commercialization to address highly prevalent diseases.

Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is advancing a novel synthetic lethal and immune activating pipeline. Leading its portfolio, Volastra has two KIF18A inhibitors in Phase 1 clinical trials for cancers with high levels of chromosomal instability.

Woolsey Pharmaceuticals is a biopharmaceutical company that provides therapeutics common diseases.

With over 50 years of experience in generic pharmaceuticals, we provide superior customer care and stay true to our core values, creating opportunities for our customers, our markets, our products and our people. We provide affordable, necessary generic pharmaceuticals to enhance the lives of patients among many therapeutic categories.

We are dedicated to the discovery and development of small molecule therapeutics targeting fundamental biological pathways of cancer. Our experienced team is comprised of industry leaders with proven track records in the discovery, clinical development, and commercialization of innovative cancer therapies. Leveraging our extensive industry experience and know-how, we developed our Integrated Discovery Engine—our working model for generating potentially differentiated product candidates that are designed to target distinct cancer pathways. This approach has allowed us to advance a diverse pipeline in a capital efficient manner, clearing four INDs with the FDA in five years. We believe our deep pipeline of oncology therapeutic candidates has the potential to significantly improve the lives of patients with various types of cancer. In May 2020, we established Zentera Therapeutics, our majority-owned Chinese joint venture, to develop and commercialize three Zentalis-discovered oncology candidates (ZN-c5, ZN-c3, and ZN-d5), in addition to potential future candidates, in China. The launch of Zentera is a key milestone in our global clinical development strategy and is the first step toward advancing our potentially best-in-class therapeutic candidates to markets worldwide.

Launched by Zentalis in 2020. Zentera Therapeutics is focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer.

ZeptoMetrix, an antylia scientific company, brings together some of the world's leading scientists in the fight against infectious disease. We are proud to offer an extensive range of research products and services that are continuously expanding. Our Mission "Partner to our Customer" is the basis for our successful collaboration with scientists across the globe.